阿立哌唑/盐酸舍曲林(Aripiprazole/Sertraline Hydrochloride) - 药物靶点：5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor x SERT_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Aripiprazole/sertraline、Sertraline/aripiprazole

靶点

5-HT1A receptor x 5-HT2A receptor x D2 receptor x D3 receptor x SERT

作用机制

5-HT1A receptor激动剂(5-羟色胺1A受体激动剂)、5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor激动剂(多巴胺D2受体激动剂)

+ [2]

治疗领域

其他疾病

在研适应症-

非在研适应症

重度抑郁症

原研机构

Otsuka Holdings Co., Ltd.

在研机构-

非在研机构

Otsuka Pharmaceutical Co., Ltd.Otsuka Holdings Co., Ltd.

最高研发阶段终止申请上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C17H18Cl3N

InChIKeyBLFQGGGGFNSJKA-XHXSRVRCSA-N

CAS号79559-97-0

查看全部结构式(2)

关联

4

项与阿立哌唑/盐酸舍曲林相关的临床试验

NCT03342963

/ Completed临床1期

A Single-center, Open-label, Randomized, Two-treatment, Two-period Crossover Trial to Investigate Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults

To investigate the bioequivalence of aripiprazole between administration of one ASC-01 tablet (aripiprazole 3 mg/sertraline 100 mg combination drug) and concomitant administration of one aripiprazole 3-mg tablet and two sertraline 50-mg tablets (Cohort 1).
To investigate food effect on plasma pharmacokinetics of aripiprazole and sertraline by single oral administration of ASC-01 under a fasting or fed condition (Cohort 2).

开始日期2017-11-21

申办/合作机构

Otsuka Pharmaceutical Co., Ltd.

JPRN-jRCT2080222363

/ Completed临床3期

A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients with Major Depressive Disorder

开始日期2014-02-25

申办/合作机构

Otsuka Pharmaceutical Co., Ltd.

NCT02046564

/ Completed临床3期

A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder

To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.

开始日期2014-02-01

申办/合作机构

Otsuka Pharmaceutical Co., Ltd.

100 项与阿立哌唑/盐酸舍曲林相关的临床结果

登录后查看更多信息

100 项与阿立哌唑/盐酸舍曲林相关的转化医学

登录后查看更多信息

100 项与阿立哌唑/盐酸舍曲林相关的专利（医药）

登录后查看更多信息

5

项与阿立哌唑/盐酸舍曲林相关的文献（医药）

2002-11-01·The Plant Journal1区 · 生物学

The plant disease resistance gene Asc‐1 prevents disruption of sphingolipid metabolism during AAL‐toxin‐induced programmed cell death

1区 · 生物学

Article

作者: Stefka D. Spassieva ; Jacques Hille ; Jonathan E. Markham

SummaryThe nectrotrophic fungus Alternaria alternata f.sp. lycopersici infects tomato plants of the genotype asc/asc by utilizing a host‐selective toxin, AAL‐toxin, that kills the host cells by inducing programmed cell death. Asc‐1 is homologous to genes found in most eukaryotes from yeast to humans, suggesting a conserved function. A yeast strain with deletions in the homologous genes LAG1 and LAC1 was functionally complemented by Asc‐1, indicating that Asc‐1 functions in an analogous manner to the yeast homologues. Examination of the yeast sphingolipids, which are almost absent in the lag1Δlac1Δ mutant, showed that Asc‐1 was able to restore the synthesis of sphingolipids. We therefore examined the biosynthesis of sphingolipids in tomato by labeling leaf discs with l‐[3‐3H]serine. In the absence of AAL‐toxin, there was no detectable difference in sphingolipid labeling between leaf discs from Asc/Asc or asc/asc leaves. In the presence of pathologically significant concentrations of AAL‐toxin however, asc/asc leaf discs showed severely reduced labeling of sphingolipids and increased label in dihydrosphingosine (DHS) and 3‐ketodihydrosphingosine (3‐KDHS). Leaf discs from Asc/Asc leaves responded to AAL‐toxin treatment by incorporating label into different sphingolipid species. The effects of AAL‐toxin on asc/asc leaflets could be partially blocked by the simultaneous application of AAL‐toxin and myriocin. Leaf discs simultaneously treated with AAL‐toxin and myriocin showed no incorporation of label into sphingolipids or long‐chain bases as expected. These results indicate that the presence of Asc‐1 is able to relieve an AAL‐toxin‐induced block on sphingolipid synthesis that would otherwise lead to programmed cell death.

1996-02-01·Experimental Cell Research

A Novel Recognition Site on Laminin for the α3β1 Integrin

Article

作者: Amy P.N. Skubitz ; Sugit Pattaramalai ; Keith M. Skubitz

Synthetic peptide GD-2 is a sequence of amino acids derived from the carboxy-terminal long arm of the A chain of laminin. Previous studies have shown that peptide GD-2 promotes the adhesion of human squamous cell carcinoma (SCC) cells as well as a variety of other cell lines. In this study, we attempted to identify the receptor that SCC cells use to adhere to peptide GD-2. Monoclonal antibodies (mAbs) against a human SCC cell line were generated. One of these mAbs, ASC-1, bound to the surface of SCC cells as determined by flow cytometry. This mAb inhibited SCC cell adhesion to peptide GD-2 and laminin, but not fibronectin or type IV collagen, suggesting that mAb ASC-1 binds to the SCC receptor for the peptide GD-2 sequence of laminin. MAb ASC-1 immunoprecipitated a complex composed of two components of 135 and 116 kDa. Immunoadsorption of ASC-1-binding material from the SCC cell extract by incubation with mAb ASC-1 resulted in the removal of the alpha 3 beta 1 integrin from the extract. Immunohistochemical staining of tissue from a normal human tongue and from a patient with SCC of the tongue revealed that mAb ASC-1 stained the surface of epithelial cells that were in contact with the basement membrane, as well as those cells located two to three layers above the basement membrane. This mAb also stained blood vessels in the squamous tissue. This staining pattern was identical to that observed when the same tissues were stained by a mAb against the alpha 3 integrin subunit. In summary, by use of a new mAb, ASC-1, that recognizes the alpha 3 beta 1 integrin, we have determined that the alpha 3 beta 1 integrin mediates SCC cell adhesion to the peptide GD-2 sequence within laminin.

1991-09-01·American journal of veterinary research

Influence of sedative and anesthetic agents on intradermal skin test reactions in dogs.

Article

作者: Eicker, S W ; Moriello, K A

To determine the effects of 9 sedative/anesthetic drug protocols on intradermal skin testing, an experimental state of type-I hypersensitivity was created. Intradermal skin tests were performed on 6 dogs, using positive and negative controls and a series of tenfold dilutions of Asc-1 allergen prior to drug administration. Approximately 4 hours later, the dogs were given 1 of the following drugs: acepromazine (low dose and high dose); ketamine hydrochloride with diazepam; thiamylal; oxymorphone; halothane; methoxyflurane; or isoflurane. The intradermal skin test then was repeated, and was scored objectively and subjectively. Objective scores were unaffected by any of the drugs. Subjective scores were affected in that acepromazine decreased wheal size and the induration of the intradermal skin test reaction sites.

100 项与阿立哌唑/盐酸舍曲林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	阿立哌唑/盐酸舍曲林	-	-

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
重度抑郁症	申请上市	-	Otsuka Holdings Co., Ltd.	-
重度抑郁症	申请上市	-	Otsuka Holdings Co., Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03342963 (CTgov)	临床1期	-	74	aripiprazole+sertraline+ASC-01 (ASC-01)	醖繭範蓋積築網觸膚餘(鑰積糧艱蓋築窪繭鬱壓) = 齋憲膚憲簾築範窪廠醖窪夢齋鹽鹽餘夢選壓網 (觸範夢築構鹽鹹蓋簾醖, 網範積蓋齋範繭糧壓艱 ~ 醖築襯膚壓範獵膚築鏇) 更多	-	2021-05-03
				Aripiprazole+Sertraline (Aripiprazole/Sertraline Concomitant)	醖繭範蓋積築網觸膚餘(鑰積糧艱蓋築窪繭鬱壓) = 夢襯構廠繭襯獵壓獵鏇窪夢齋鹽鹽餘夢選壓網 (觸範夢築構鹽鹹蓋簾醖, 蓋構夢艱夢獵獵範蓋獵 ~ 鹽艱繭淵衊範蓋憲齋衊) 更多
NCT02046564 (CTgov)	临床3期	重度抑郁症	412	ASC-01 (ASC-01)	繭淵築鹹鑰製艱製窪鹽(壓膚窪衊齋簾願選淵鑰) = 願範糧範窪襯網簾壓構夢選繭糧壓窪鏇鏇廠網 (築鏇獵齋齋簾範餘繭醖, 淵繭願蓋餘壓網鏇製積 ~ 獵積憲選衊憲網廠獵構) 更多	-	2018-05-21
				Placebo (Placebo)	繭淵築鹹鑰製艱製窪鹽(壓膚窪衊齋簾願選淵鑰) = 襯鑰顧鬱壓範構顧鬱遞夢選繭糧壓窪鏇鏇廠網 (築鏇獵齋齋簾範餘繭醖, 鹽顧鏇壓夢範窪鏇餘衊 ~ 鑰網網鑰艱夢壓顧艱餘) 更多